Revvity, Inc. (RVTY)

Market Cap	10.73B
Revenue (ttm)	2.81B
Net Income (ttm)	237.48M
Shares Out	116.07M
EPS (ttm)	1.99
PE Ratio	46.34
Forward PE	17.43
Dividend	$0.28 (0.30%)
Ex-Dividend Date	Jan 16, 2026

Volume	501,776
Open	92.58
Previous Close	93.59
Day's Range	90.73 - 93.12
52-Week Range	81.36 - 129.50
Beta	0.99
Analysts	Buy
Price Target	117.43 (+26.99%)
Earnings Date	Oct 27, 2025

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and dise...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1937
• Employees: 11,000
• Stock Exchange: NYSE
• Ticker Symbol: RVTY
• Website: https://www.revvity.com

Financial Performance

In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.

Analyst Summary

According to 15 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $117.43, which is an increase of 26.99% from the latest price.

Price Target

$117.43

(26.99% upside)

Analyst Consensus: Buy